Pharmacogenomic information in drug labels: European Medicines Agency perspective. - Wikidata - awgldk - TriplyDB

Pharmacogenomic information in drug labels: European Medicines Agency perspective.

Pharmacogenomic information in drug labels: European Medicines Agency perspective.

http://www.wikidata.org/entity/Q38364391

about

Pharmacogenomics in the clinic The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.The genetics of drug efficacy: opportunities and challenges.What is the future of pharmacogenomics in pain management?Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.DNA Methylation of ADME Genes.Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations.Personalized medicine: what are the challenges for health services?From genomic medicine to precision medicine: highlights of 2015.Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice.Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.Applications of pharmacogenomics in regulatory science: a product life cycle review.Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years.Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.Integrating rare genetic variants into pharmacogenetic drug response predictions.

P2860

Q26782786-51BDEB15-006E-443A-8527-A10295145174 Q28080256-40F457BC-9DBF-49BD-8333-4EE57C3CEDE1 Q28554199-5E9733E8-79EE-45D8-AFE2-ADB1790900FC Q33909349-8F90E59B-7428-4FB6-89D5-143813C12E36 Q35812195-F0DB8DC5-E41B-40AA-84A4-18B916B61B75 Q35998552-BAB186A2-D089-46B2-90D3-4A8D8EA84545 Q38654780-4075500B-B6F1-4A3D-BB9B-380FC746DC5B Q38773033-62E56498-7FA0-4A64-8965-532D5CF898F3 Q38780828-AE28A483-AF7F-41D4-82E2-37330182954F Q38802517-BB65952D-A8B1-4B34-AEA2-B84EBD85DC69 Q38802927-B7698025-A70A-488D-9819-C263BD2B2E64 Q38848409-F6988DFF-FB6B-41B7-AC8F-E3013D2B173B Q39833609-90794BE9-F3E7-4808-A8AE-C547BF70E64F Q40197692-158D5B99-A65D-42F8-B202-6EE96B4BFD96 Q40368410-5610F871-2ADB-401E-BF98-C782202AD387 Q40462722-6C20F668-57C7-44C7-A7CB-0908F13975A0 Q42537218-DC745447-3F88-4AD7-B6FF-51EF9FDC5E7B Q44123954-1F43ACB0-D09E-469B-81BF-84A80BE8467A Q47277562-64224719-0476-481B-B662-E5AF10F1347E Q47284170-F1D885A5-8CF1-433E-BCFC-86251A298870 Q48585125-B7D9BDBB-87D1-40CB-82C7-C35E0AC6258E Q48861311-E8352B73-196C-47B3-948E-0E769AE94C9E Q54940794-A95F8CDE-24F2-4DEB-A97B-D23053B7861F

P2860

Pharmacogenomic information in drug labels: European Medicines Agency perspective.

http://www.wikidata.org/entity/Q38364391

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Pharmacogenomic information in drug labels: European Medicines Agency perspective.

@en

type

label

Pharmacogenomic information in drug labels: European Medicines Agency perspective.

@en

prefLabel

Pharmacogenomic information in drug labels: European Medicines Agency perspective.

@en

P1433

Q38364391-DCDE585C-5364-4B6C-BE3B-9FB86C6BD269

P1476

Q38364391-076B9907-0476-4D67-8698-87350D96558F

P2093

Q38364391-1D4C3EEF-68C7-48E3-A762-82EDA006AE13

Q38364391-79C6C429-BFC9-43E9-923A-2C1DDA056487

Q38364391-820E01D3-5D72-49B8-84C6-CB963612751D

Q38364391-B525C6EB-37ED-46E7-8DB1-8A2576CE6FCF

Q38364391-C9D4496F-83FE-4053-82A6-D2B7953725E4

Q38364391-EA06692B-D2F2-46E9-835F-92128BF1D928

Q38364391-EA3EE73C-290F-4B47-A8FC-BFE773070291

P2860

Q38364391-030C4DEF-E8E4-41F5-A9F8-C50DC1365770

Q38364391-1E73B022-92BF-4E0F-A0D7-958CD3D93B64

Q38364391-2F91E916-7A13-4E99-BE15-F30D6130860E

Q38364391-383F8673-4C9F-4B7C-8A44-45DEA0334B8B

Q38364391-536DCE6E-3C10-4953-8739-385199103A3F

Q38364391-61C7D513-7CD5-4CC7-9291-7BABBBB1C1C9

Q38364391-6F61E7A6-DA72-41D9-9FDC-C1A8B70455E1

Q38364391-79EC34F5-399A-4D2B-A3CB-12CC73022821

Q38364391-A554F61C-CC87-4A89-9B21-45D68DA969F8

Q38364391-AEF6E4A8-05B4-46A4-B1FC-61548A32A216

P2888

Q38364391-126F2F15-0157-4820-AFDE-0CCC3F204648

P304

Q38364391-49822727-16A8-485F-8FEB-B976D8E1038B

P31

Q38364391-C2BABD9B-7C19-4F83-A9C6-9F22F9E56266

P356

Q38364391-7BA249DA-7040-4E5F-8578-6C2E59F56E8C

P433

Q38364391-10CADEEB-1230-4DF1-974E-226BF153C67E

P478

Q38364391-D07AAF30-8F61-47D1-90BB-65411AF4C35E

P50

Q38364391-02B2E20D-E89B-4805-8904-B10B11DB3475

Q38364391-13EFC8C9-E665-479A-BC35-80C324B6E1A1

P577

Q38364391-8CBBF6A7-C678-474D-843C-1BB75810E211

P5875

Q38364391-BF65C2C9-1EC8-4E0E-9F43-F60FD2D09E6A

P6179

Q38364391-79FF4B95-B83D-41B2-A75D-8DC7F82B726B

P698

Q38364391-5E11D0E0-E012-45AA-B305-367B62E74AE9

P921

Q38364391-0D00E775-2DC4-4B5E-BA8A-64D22F8E03A7

P356

P1433

The Pharmacogenomics Journal

P1476

Pharmacogenomic information in drug labels: European Medicines Agency perspective

@en

P2093

F Ehmann

http://www.w3.org/2001/XMLSchema#string

K Prasad

http://www.w3.org/2001/XMLSchema#string

L Caneva

http://www.w3.org/2001/XMLSchema#string

M Ingelman-Sundberg

http://www.w3.org/2001/XMLSchema#string

M Maliepaard

http://www.w3.org/2001/XMLSchema#string

M Papaluca-Amati

http://www.w3.org/2001/XMLSchema#string

M Paulmichl

http://www.w3.org/2001/XMLSchema#string

P2860

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Response variability to P2Y12 receptor inhibitors: expectations and reality

HLA-B*5701 screening for hypersensitivity to abacavir.

Policies to aid the adoption of personalized medicine

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Pharmacogenomics and individualized drug therapy.

An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Pathology practice and pharmacogenomics.

Ethical and social issues in pharmacogenomics testing.

P2888

P304

201-210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/TPJ.2014.86

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Adrián Llerena

P577

2015-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272844550

http://www.w3.org/2001/XMLSchema#string

P6179

1053682676

http://www.w3.org/2001/XMLSchema#string

P698

25707393

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics